GlassScriptPhysician profile
Russell Dambra
NPI 1154381929
$2,892.49
in general payments reported to CMS, 2019-2025
39 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $473 · 2022: $44.20 · 2023: $470 · 2024: $853 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.32 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $268.47 | 2019-2025 | Evenity, Prolia, Repatha |
| Xeris Pharmaceuticals, INC. | $213.32 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $201.80 | 2019-2025 | Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $172.56 | 2019-2024 | |
| Abbvie INC. | $170.83 | 2019-2025 | Synthroid |
| Radius Health, INC. | $132.58 | 2020-2025 | Tymlos |
| Mannkind Corporation | $111.83 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $83.60 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $81.85 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $80.71 | 2019-2024 | Strensiq |
| Abbott Laboratories | $78.68 | 2020-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $78.26 | 2019-2020 | |
| Corcept Therapeutics | $76.68 | 2023-2024 | Korlym |
| Amarin Pharma, INC. | $74.88 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Dambra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.